Boucherville, September 1st, 2015 - Sandoz Canada Inc., a Novartis company, has received approval from Health Canada for a number of additional indications for PrOmnitrope® (somatropin), a recombinant human growth hormone used to treat growth problems in both pediatric and adult patients. PrOmnitrope® is Canada's first subsequent entry biologic (biosimilar), which are follow-on versions of original biological molecules and, unlike most generic copies of chemical medicines, undergo their own safety and efficacy clinical studies.
